• #AAN2018 – H.P. Acthar Gel Shows Promise as Therapy to Delay Progression of ALS
  • #AAN2018 – New Molecular Therapies May Be Treatment Strategy for ALS, Study Suggests
  • #AAN2018: Variations of TP73 Gene May Increase Susceptibility to Non-inherited ALS, Study Reports
  • How I Use ‘Showing Up’ to Help Me Live with ALS
  • #AAN2018 — NurOwn’s Beneficial Effect in ALS Sustained by miRNA Regulation, Study Suggests
  • Tailored Home Exercises May Improve Daily Living of Early-stage ALS Patients, Small Study Suggests
  • New Study Reveals Two Genes Associated with High Risk for ALS
  • NIH Agency Pioneers Collaborative Research into Rare Diseases
  • NMD Obtains $47 Million in New Financing for Its ALS Therapy Program
  • Canada Accepts New Drug Submission, Grants Priority Review for Edaravone to Treat ALS
  • Rilutek Prolongs Survival of ALS Patients in Later Stages, Study Shows
  • AveXis and Its Potential ALS Gene Therapy to Be Purchased by Novartis for $8.7B